Results 121 to 130 of about 34,736 (209)

Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy

WIREs Nanomedicine and Nanobiotechnology, Volume 18, Issue 2, March/April 2026.
Myeloid‐derived suppressor cells (MDSCs) are key contributors to cancer immunotherapy failure and major targets in new therapeutic strategies. We highlight therapeutic approaches to counteract their immunosuppressive functions and discuss recent efforts to optimize drug delivery for controlling MDSCs, focusing on resiquimod as a representative drug ...
Yanying He, Yoon Yeo
wiley   +1 more source

Understanding Prebiotic Allergy: An Evaluation of Basophil Activation Induced by Galacto‐Oligosaccharides

Clinical and Translational Allergy, Volume 16, Issue 3, March 2026.
Si Yuan Leow, Hongmei Wen, Jian Yi Soh, Wen Chin Chiang, Youjia Zhong, Elizabeth Huiwen Tham, Wenyin Loh, Si Hui Goh, Dianne J. Delsing, Bee Wah Lee, Chiung‐Hui Huang   +10 more
wiley   +1 more source

Secretory autophagy and epithelial‐to‐mesenchymal transition in cadaveric AMD samples: Novel pathways in disease progression

Acta Ophthalmologica, Volume 104, Issue 2, Page 239-251, March 2026.
Abstract Purpose To examine the presence of secretory autophagy and epithelial–mesenchymal transition (EMT) in the macular retinal pigment epithelium (RPE) of human cadaver eyes with different forms of age‐related macular degeneration (AMD). Methods Human cadaver macula samples representing dry and wet AMD, as well as age‐matched controls, were ...
Iswariyaraja Sridevi Gurubaran, Ali Koskela, Hanna Heloterä, Kai Kaarniranta   +3 more
wiley   +1 more source

Galectin-3 in AKI: Pathogenic Target, Diagnostic Biomarker, or Both? [PDF]

Int J Biol Sci
Gui Y, Zhou D.
europepmc   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1250-1270, March 2026.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Surface Avidity of Anionic Polypeptide Coatings on Layer‐by‐Layer Nanoparticles Target Cancer‐Associated Amino Acid Transporters

Angewandte Chemie, Volume 138, Issue 8, 16 February 2026.
Electrostatically layered nanoparticles (NPs) coated with anionic polypeptides selectively target cancer cells by engaging amino acid transporters. Poly(L‐glutamate) (PLE) coatings cluster the glutamine transporter SLC1A5, prolonging NP surface retention, while poly(L‐aspartate) (PLD) coatings also bind SLC1A3, potentially promoting faster ...
Ivan S. Pires, Margaret M. Billingsley, Ezra Gordon, Andrew J. Pickering, Eva Cai, Gonzalo J. Esparza, Mae L. Pryor, Alexander D. Stoneman, Aidan Kindopp, Darrell J. Irvine, Paula T. Hammond   +10 more
wiley   +2 more sources

Galectin-3 in the Lateral Ventricle Regulates Immune Functions. [PDF]

ASN Neuro
Soares LC, Bernhardova H, Szele FG.
europepmc   +1 more source

Leveraging the ADAM10 prodomain for selective inhibition to enhance recovery after myocardial infarction

British Journal of Pharmacology, Volume 183, Issue 5, Page 990-1008, March 2026.
Background and Purpose Inflammation plays a crucial role in the development and progression of numerous acute and chronic diseases such as myocardial infarction (MI) and heart failure. Targeting ADAM proteases, particularly ADAM10, holds promise for fine‐tuning inflammatory responses.
Erik Klapproth, Johanna Marks, Patrick Diaba‐Nuhoho, Sören Grell, Paul Leubauer, Susanne Kämmerer, Johannes R. Soltwedel, Fred Rasmussen, Felix Mejia, Marcia L. Moss, Christopher Prince, Peter Mirtschink, Ben Wielockx, Paul Saftig, Michael Wagner, Kristina Lorenz, Ali El‐Armouche   +16 more
wiley   +1 more source

Glycoengineering CAR-T cells to overcome galectin-3-mediated immunosuppression. [PDF]

Front Immunol
Lau LS, Suarez M, Fernandez B, Souchak J, Antonopoulos A, Hu N, Abreu MM, Koehne G, Dell A, Haslam SM, Posey AD, Dimitroff CJ.   +11 more
europepmc   +1 more source

SUSD2 Promotes Metastasis and Primary Tumor Growth in Pancreatic Cancer Cells via Integrin–FAK Signaling Activation

Cancer Science, Volume 117, Issue 3, Page 711-726, March 2026.
This study investigates the role of Sushi domain‐containing 2 (SUSD2) in pancreatic ductal adenocarcinoma (PDAC) and demonstrates that SUSD2 enhances both metastasis and primary tumor growth by promoting integrin β1–FAK signaling. SUSD2 interacts with integrin β1, enhancing adhesion to extracellular matrix (ECM) components such as collagen 1 and ...
Junjiro Yoshida, Tomokazu Ohishi, Isao Momose, Shun‐ichi Ohba, Kyohei Kurosawa, Akiko Harakawa, Hiroyuki Inoue, Minori Senoo, Daisuke Tatsuda, Hikaru Abe, Atsushi Masamune, Manabu Kawada   +11 more
wiley   +1 more source